ArticleBriefings in bioinformatics2024
BANDRP: a bilinear attention network for anti-cancer drug response prediction based on fingerprint and multi-omics.
Article in Briefings in bioinformatics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- RLASON-CDR: a reinforcement learning-driven adaptive synergistic optimization network for cancer drug response prediction.Briefings in bioinformatics · 2026Article
- OmicsTransformer: self-supervised masked consistency and uncertainty-aware fusion for robust multi-omics prediction.Bioinformatics (Oxford, England) · 2026Article
- MDCDR: predicting cancer drug response via multimodal feature fusion and feature disentanglement.Briefings in bioinformatics · 2026Article
- MoGraphDRP: Multi-omics and graph fusion with bilinear attention for predicting drug sensitivity.PloS one · 2026Article
- A Knowledge-Enhanced Multimodal Framework with Genomic Reconstruction for DLBCL Drug Response Prediction.Computational and structural biotechnology journal · 2026Article
- Pharmacogenomics of Tirzepatide: Genomic Insights into Dual GIP/GLP-1 Agonist Response in Type 2 Diabetes and Atherosclerosis.Pharmaceuticals (Basel, Switzerland) · 2025Review
- BBANsh: a deep learning architecture based on BERT and bilinear attention networks to identify potent shRNA.Briefings in bioinformatics · 2025Article
- DeepCCDS: Interpretable Deep Learning Framework for Predicting Cancer Cell Drug Sensitivity through Characterizing Cancer Driver Signals.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Multi-omics modality completion and knowledge distillation for drug response prediction in cervical cancer.Frontiers in oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Predicting anti-cancer drug response can help with personalized cancer treatment and is an important topic in modern oncology research. Although some methods have been used for anti-cancer drug response prediction, how to effectively integrate various features related to cancer cell lines, drugs, and their known responses is still affected by the redundant information of input features and the complex interactions between features. In this study, we propose a bilinear attention model, named BANDRP, based on multiple omics data of cancer cell lines and multiple molecular fingerprints of drugs to predict potential anti-cancer drug responses. Compared with existing models, BANDRP uses gene expression data to calculate pathway enrichment scores to enrich the features of cancer cell lines and can automatically learn the interactive information of cancer cell lines and drugs through bilinear attention networks. Benchmarking and independent tests demonstrate that BANDRP surpasses baseline models and exhibits robust generalization performance. Ablation experiments affirm the optimality of the current model architecture and feature selection scheme for our prediction task. Furthermore, analytical experiments and case studies on unknown anti-cancer drug response predictions underscore BANDRP's potential as a potent and reliable framework for predicting anti-cancer drug response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.